Evidence Hub

Letter in response to “Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial” by Sarkar et al

N. Marrouche, H. Williams

Indian Journal of Dermatology, Venereology and Leprology, 2018

1 citation

Abstract

© 2017 Indian Journal of Dermatology, Venereology and Leprology | Published by Wolters Kluwer Medknow Sir, Current international guidelines on managing chronic urticaria are based on evidence from published literature where available. However, there is a scarcity of clinical trials even among well‐established therapeutic options. We thank the authors for addressing an important evidence gap by conducting a randomized controlled trial to test the comparability of a standard dose of levocetirizine 5 mg plus montelukast 10 mg and doubling the dose of levocetirizine to 10 mg. We wish to share a number of observations that would benefit from some clarification from the authors.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free